Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

BeOne Medicines Ltd (6160N) Stock Price & Analysis

6160N Stock Chart & Stats

No data to display
Day’s Range
N/A
52-Week Range
N/A
Previous Close
N/A
Volume
N/A
Average Volume (3M)
N/A
Market Cap
MXN 778.04B
Enterprise Value
MXN 231.34B
Total Cash (Recent Filing)
MXN 5.10B
Total Debt (Recent Filing)
MXN 1.14B
Price to Earnings (P/E)
62.0
Beta
N/A
Next Earnings
Nov 06, 2026 (Est.)
EPS Estimate
2.72
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Profitability And Margins

The return to profitability, combined with consistently very high gross margins, indicates stronger earnings economics and meaningful product value. If maintained, this margin structure can support reinvestment in oncology research, commercialization, and expansion while improving resilience over the next several quarters.

Cash Generation

Strong operating and free cash flow gives BeOne internal funding for clinical development, regulatory activity, and commercial growth without relying solely on external capital. Free cash flow equal to about 85% of net income also supports the credibility and durability of the recent earnings recovery.

Regulatory And Clinical Progress

The FDA approval converts positive Phase 3 evidence into an expanded commercial treatment opportunity in first-line HER2-positive gastroesophageal cancer. The demonstrated survival advantage strengthens the oncology portfolio, supports adoption potential, and can extend the company’s durable revenue base.

Bears Say

Slowing Revenue Growth

Revenue growth has decelerated despite the return to profitability, making future earnings expansion more dependent on execution, new indications, and sustained product uptake. Slower top-line growth can limit operating leverage and makes it harder for the company to compound results at its historical pace.

Cash-flow Consistency

Current cash generation is encouraging, but the recent history of materially negative cash flows shows that consistency has not yet been fully established. Operating cash flow below net income also points to timing or working-capital effects, which could make internally funded investment less predictable.

Rising Leverage

The increase in debt relative to equity reduces financial flexibility compared with the prior year, even though current leverage remains moderate and equity has built over time. If earnings volatility returns, higher leverage could constrain investment choices and increase pressure on future cash allocation.

BeOne Medicines Ltd News

6160N FAQ

What is BeOne Medicines Ltd’s market cap?
BeOne Medicines Ltd’s market cap is Mex$778.04B.
When is BeOne Medicines Ltd’s upcoming earnings report date?
BeOne Medicines Ltd’s next earnings report is estimated for Nov 06, 2026 (not yet confirmed), which is in 3 days.
How were BeOne Medicines Ltd’s earnings last quarter?
BeOne Medicines Ltd released its earnings results on Aug 05, 2026. The company reported Mex$2.929 earnings per share for the quarter, beating the consensus estimate of Mex$2.37 by Mex$0.559.
Is BeOne Medicines Ltd overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does BeOne Medicines Ltd pay dividends?
BeOne Medicines Ltd does not currently pay dividends.
What is BeOne Medicines Ltd’s EPS estimate?
BeOne Medicines Ltd’s EPS estimate is 2.72.
What happened to BeOne Medicines Ltd’s price movement after its last earnings report?
BeOne Medicines Ltd reported an EPS of Mex$2.929 in its last earnings report, beating expectations of Mex$2.37. Following the earnings report the stock price went same ―.
Which hedge fund is a major shareholder of BeOne Medicines Ltd?
Currently, no hedge funds are holding shares in MX:6160N
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology